SCR 68 is a California Senate Concurrent Resolution that declares the week of May 5, 2025, as Tardive Dyskinesia Awareness Week. The resolution recites clinical risk factors and prevalence estimates, cites the American Psychiatric Association's recommendation for routine TD screening, references FDA‑approved treatments, and urges education and awareness among providers, patients, and care partners.
The measure is purely declaratory: it signals legislative concern about TD, encourages screening and outreach, and requests distribution of the resolution, but it does not appropriate funds, create regulatory mandates, or change clinical licensing or reimbursement rules. Its practical effect will depend on whether public health agencies, provider groups, insurers, or advocacy organizations take action in response to the recognition week.
At a Glance
What It Does
The resolution formally designates the week beginning May 5, 2025 as Tardive Dyskinesia Awareness Week and includes legislative findings describing TD, its risk groups, and available FDA‑approved treatments. It urges TD screening education for health care providers, patients, and care partners and asks the Secretary of the Senate to transmit copies for distribution.
Who It Affects
Clinicians who prescribe antipsychotics, mental health clinics, academic medical centers, patient and caregiver advocacy organizations, and state public health entities are the primary audiences. The text does not impose reporting, funding, or compliance obligations on any party.
Why It Matters
Although symbolic, the resolution elevates TD on the state’s public health radar and may prompt voluntary actions — such as CME programs, screening protocols in clinics, or advocacy campaigns — that could increase diagnosis rates and referrals for treatment. Because it contains no funding or mandate, the resolution's ability to change care depends on downstream actors adopting concrete measures.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SCR 68 is a short, nonbinding legislative statement that bundles medical background, clinical guidance references, and a formal declaration into a single page. The "whereas" clauses summarize why lawmakers are signaling attention: rising antipsychotic prescribing, known risk factors for TD, a substantial undiagnosed population, the role of routine screening in clinical guidelines, and the existence of FDA‑approved therapies.
Those recitals form the factual rationale legislators use to justify the awareness week.
The operative text does three things: it names the week of May 5, 2025 as Tardive Dyskinesia Awareness Week; it emphasizes the importance of early detection, screening, and education for healthcare providers, patients, and care partners; and it directs the Secretary of the Senate to transmit copies of the resolution. There are no directives to state agencies, no new reporting duties, no budget language, and no enforcement mechanism — the resolution functions as a policy signal rather than an implementable program.For practitioners and health system leaders, the document matters because governments and professional groups often use awareness weeks as the springboard for trainings, clinical reminders, or public communications.
A named week can justify CME modules, patient‑education materials, screening drives in outpatient clinics, or partnerships between state public health and advocacy groups. But none of those follow‑on actions are required by the resolution; they must be undertaken voluntarily or be funded through separate appropriations or grants.Finally, the resolution locates TD within existing clinical guidance by citing the American Psychiatric Association’s recommendation for routine screening and by noting FDA‑approved treatment options.
That framing leans on professional standards to encourage practice change without compelling it. The measure therefore can alter norms and expectations — for example, increasing provider attention to abnormal movements in patients on antipsychotics — while leaving regulatory, reimbursement, and clinical‑practice changes to other authorities and organizations.
The Five Things You Need to Know
The resolution formally designates the week of May 5, 2025 as Tardive Dyskinesia Awareness Week in California.
It lists populations at elevated TD risk — including people over 55, Black individuals, women, those with mood or substance use disorders, intellectual disabilities, CNS injuries, and people with high cumulative antipsychotic exposure.
The text explicitly cites the American Psychiatric Association’s recommendation for routine TD screening and notes that FDA‑approved treatments exist.
SCR 68 urges TD screening education for health care providers, patients, and care partners but creates no legal mandates, reporting duties, or appropriations.
The resolution instructs the Secretary of the Senate to transmit copies to the author for distribution, a clerical step to disseminate the declaration to stakeholders.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Factual findings and clinical context
The whereas clauses compile medical and epidemiological claims used to justify the awareness week: rising antipsychotic use, the nature of TD, estimated underdiagnosis, higher‑risk groups, and reference to clinical guidance and FDA‑approved treatments. Practically, these recitals signal the legislature’s baseline facts and identify populations and clinical touchpoints that advocacy and public‑health actors might target for outreach.
Designation of Tardive Dyskinesia Awareness Week
This operative line creates the formal recognition — the legislature declares the week of May 5, 2025 as TDAW. The language is symbolic: it gives organizations a named occasion to coordinate activities, but it imposes no obligations on agencies, providers, or payers and carries no regulatory force.
Encouragement of screening, education, and awareness
The resolution underscores the importance of early detection and supports efforts to raise awareness about TD causes and symptoms. This encouragement may influence professional societies, health systems, and advocacy groups to prioritize screening training or patient materials, but because the resolution lacks funding or statutory authority, any operational programs would arise from subsequent actions by those bodies.
Distribution to stakeholders
The final provision directs the Secretary of the Senate to transmit copies of the resolution to the author for distribution. This administrative step is the mechanism for dissemination; it does not identify responsible agencies for follow‑up or require reporting on outcomes, which leaves implementation diffuse and voluntary.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Adults living with TD or experiencing abnormal movements — increased visibility may lead to more screenings, earlier diagnosis, and referrals to treatment.
- Patient and caregiver advocacy organizations — the awareness week provides a legislative imprimatur that can help with fundraising, outreach campaigns, and partnerships with clinical groups.
- Mental health clinicians and specialty clinics — the declaration offers a rationale for instituting or expanding routine movement‑disorder screening protocols and continuing education on TD.
- Academic centers and CME providers — an official awareness week creates demand for educational content, case conferences, and training modules focused on detection and management.
Who Bears the Cost
- State and local public health offices and advocacy groups — running outreach events, producing materials, or coordinating campaigns will consume staff time and resources unless separate funding is obtained.
- Clinics and providers — implementing more consistent screening or follow‑up may require clinician time, training, and potentially new billing or documentation practices.
- Insurers and health plans — if heightened screening leads to more diagnostic evaluations or prescriptions for FDA‑approved TD treatments, payers could see increased utilization and associated costs.
- Pharmaceutical and device manufacturers — while not a cost in the narrow sense, these companies may face increased scrutiny and demand for treatment access or will be incentivized to support awareness initiatives, which carries marketing and compliance considerations.
Key Issues
The Core Tension
The central tension is between the clear public‑health benefit of raising awareness and the risk of generating expectations for diagnosis and treatment that the health system, insurers, and providers may not be resourced to meet; the resolution nudges practice and public attention but stops short of providing the funding or regulatory mechanisms needed to ensure equitable follow‑through.
The resolution walks a familiar line for awareness proclamations: it raises attention without creating operational support. That creates a practical implementation gap — awareness can increase demand for screening and treatment but, in the absence of funding or mandated pathways, may leave clinicians and patients without clear routes for diagnosis, specialty referral, or payment.
The bill’s citation of APA guidance and FDA‑approved therapies frames the issue as clinically actionable, but it does not address coverage rules, provider capacity, or standards for who should perform routine screenings and how results should be documented or acted upon.
The measure also risks uneven impact across populations. The recitals single out higher‑risk groups, including older adults and certain racial and clinical subgroups, yet the resolution contains no mechanism to target outreach or measure disparities.
Increased awareness could reduce stigma and prompt care for some, while for others it may reveal barriers to treatment—such as lack of specialists, limits on insurance coverage for TD therapies, or geographic access problems — that the resolution does not resolve. Finally, there is a modest risk of over‑medicalization: encouraging routine screening without clear protocols may generate false positives or unnecessary interventions if clinicians lack training or standardized assessment tools.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.